Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Inezetamab

Alternative Names: Inezetamab, amg-994, amg 994, amg994
Latest Update: 2024-04-29
Latest Update Note: PubMed Publication

Product Description

Amgen is developing AMG-994 as a treatment for advanced solid tumors. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04727554)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Inezetamab

Countries in Clinic: Australia, Belgium, Canada, France, Germany, Japan, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT04727554

P1

Completed

Oncology Solid Tumor Unspecified

2023-06-05

jRCT2031210382

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

2023-03-07

Recent News Events

Date

Type

Title

04/29/2024

PubMed

 Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.

02/06/2024

PubMed

 Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report.

10/30/2023

PubMed

 Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions